Are Gadolinium-Enhanced MR Sequences Needed in Simultaneous ¹⁸F-FDG-PET/MRI for Tumor Delineation in Head and Neck Cancer?

References

1. 1.↵
   1. Schaarschmidt BM,
   2. Heusch P,
   3. Buchbender C, et al

   . Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI. Eur J Nucl Med Mol Imaging 2016;43:92–102 doi:10.1007/s00259-015-3145-z pmid:26243264

   CrossRefPubMed
2. 2.↵
   1. Xiao Y,
   2. Chen Y,
   3. Shi Y, et al

   . The value of fluorine-18 fluorodeoxyglucose PET/MRI in the diagnosis of head and neck carcinoma: a meta-analysis. Nucl Med Commun 2015;36:312–18 doi:10.1097/MNM.0000000000000248 pmid:25514551

   CrossRefPubMed
3. 3.↵
   1. Gupta B,
   2. Johnson NW,
   3. Kumar N

   . Global epidemiology of head and neck cancers: a continuing challenge. Oncology 2016;91:13–23 doi:10.1159/000446117 pmid:27245686

   CrossRefPubMed
4. 4.↵
   1. Widmann G,
   2. Henninger B,
   3. Kremser C, et al

   . MRI sequences in head & neck radiology—state of the art. Rofo 2017;189:413–22 doi:10.1055/s-0043-103280 pmid:28449168

   CrossRefPubMed
5. 5.↵
   1. Ozturk M,
   2. Yorulmaz I,
   3. Guney E, et al

   . Masses of the tongue and floor of the mouth: findings on magnetic resonance imaging. Eur Radiol 2000;10:1669–74 doi:10.1007/s003300000475 pmid:11044946

   CrossRefPubMed
6. 6.↵
   1. Ross MR,
   2. Schomer DF,
   3. Chappell P, et al

   . MR imaging of head and neck tumors: comparison of T1-weighted contrast-enhanced fat-suppressed images with conventional T2-weighted and fast spin-echo T2-weighted images. Am J Roentgenol 1994;163:173–78 doi:10.2214/ajr.163.1.8010208 pmid:8010208

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Weller A,
   2. Barber JL,
   3. Olsen OE

   . Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927–37 doi:10.1007/s00467-013-2636-z pmid:24146299

   CrossRefPubMed
8. 8.↵
   1. Weinreb JC,
   2. Abu-Alfa AK

   . Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned? J Magn Reson Imaging 2009;30:1236–39 doi:10.1002/jmri.21979 pmid:19938035

   CrossRefPubMedWeb of Science
9. 9.↵
   1. McDonald RJ,
   2. McDonald JS,
   3. Kallmes DF, et al

   . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

   CrossRefPubMed
10. 10.↵
    1. von Schulthess GK,
    2. Veit-Haibach P

    . Workflow considerations in PET/MR imaging. J Nucl Med 2014;55:19S–24S doi:10.2967/jnumed.113.129239 pmid:24790220

    Abstract/FREE Full Text
11. 11.↵
    1. Kuhn FP,
    2. Hüllner M,
    3. Mader CE, et al

    . Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed? J Nucl Med 2014;55:551–58 doi:10.2967/jnumed.113.125443 pmid:24491410

    Abstract/FREE Full Text
12. 12.↵
    1. Klenk C,
    2. Gawande R,
    3. Tran VT, et al

    . Progressing toward a cohesive pediatric 18F-FDG PET/MR protocol: is administration of gadolinium chelates necessary? J Nucl Med 2016;57:70–77 doi:10.2967/jnumed.115.161646 pmid:26471690

    Abstract/FREE Full Text
13. 13.↵
    1. Purohit BS,
    2. Ailianou A,
    3. Dulguerov N, et al

    . FDG-PET/CT pitfalls in oncological head and neck imaging. Insights Imaging 2014;5:585–602 doi:10.1007/s13244-014-0349-x pmid:25154759

    CrossRefPubMed
14. 14.↵
    1. Gupta T,
    2. Master Z,
    3. Kannan S, et al

    . Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011;38:2083–95 doi:10.1007/s00259-011-1893-y pmid:21853309

    CrossRefPubMed
15. 15.↵
    1. Kim SY,
    2. Lee S,
    3. Nam SY, et al

    . The feasibility of 18F-FDG PET scans 1 month after completing radiotherapy of squamous cell carcinoma of the head and neck. J Nucl Med 2007;48:373–78 pmid:17332614

    Abstract/FREE Full Text
16. 16.↵
    1. Varoquaux A,
    2. Rager O,
    3. Poncet A, et al

    . Detection and quantification of focal uptake in head and neck tumours: (18)F-FDG PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 2014;41:462–75 doi:10.1007/s00259-013-2580-y pmid:24108458

    CrossRefPubMed
17. 17.↵
    1. Yamaga E,
    2. Toriihara A,
    3. Nakamura S, et al

    . Clinical usefulness of 2-deoxy-2-[18F] fluoro-d-glucose-positron emission tomography/computed tomography for assessing early oral squamous cell carcinoma (cT1-2N0M0). Jpn J Clin Oncol 2018;48:633–39 doi:10.1093/jjco/hyy065 pmid:29718274

    CrossRefPubMed
18. 18.↵
    1. Kubiessa K,
    2. Purz S,
    3. Gawlitza M, et al

    . Initial clinical results of simultaneous 18F-FDG PET/MRI in comparison to 18F-FDG PET/CT in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 2014;41:639–48 doi:10.1007/s00259-013-2633-2 pmid:24292211

    CrossRefPubMed
19. 19.↵
    1. Queiroz MA,
    2. Hüllner M,
    3. Kuhn F, et al

    . PET/MRI and PET/CT in follow-up of head and neck cancer patients. Eur J Nucl Med Mol Imaging 2014;41:1066–75 doi:10.1007/s00259-014-2707-9 pmid:24577950

    CrossRefPubMed
20. 20.↵
    1. Schaarschmidt BM,
    2. Gomez B,
    3. Buchbender C, et al

    . Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area? Diagn Interv Radiol 2017;23:127–32 doi:10.5152/dir.2016.15610 pmid:28089955

    CrossRefPubMed
21. 21.↵
    1. Becker M,
    2. Varoquaux AD,
    3. Combescure C, et al

    . Local recurrence of squamous cell carcinoma of the head and neck after radio(chemo)therapy: diagnostic performance of FDG-PET/MRI with diffusion-weighted sequences. Eur Radiol 2018;28:651–63 doi:10.1007/s00330-017-4999-1 pmid:28812148

    CrossRefPubMed
22. 22.↵
    1. Queiroz MA,
    2. Wollenweber SD,
    3. von Schulthess G, et al

    . Clinical image quality perception and its relation to NECR measurements in PET. EJNMMI Phys 2014;1:103 doi:10.1186/s40658-014-0103-y pmid:26501461

    CrossRefPubMed
23. 23.↵
    1. Monti S,
    2. Cavaliere C,
    3. Covello M, et al

    . An evaluation of the benefits of simultaneous acquisition on PET/MR coregistration in head/neck imaging. J Healthc Eng 2017;2017:1–7 doi:10.1155/2017/2634389 pmid:29076331

    CrossRefPubMed
24. 24.↵
    1. Boss A,
    2. Stegger L,
    3. Bisdas S, et al

    . Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol 2011;21:1439–46 doi:10.1007/s00330-011-2072-z pmid:21308378

    CrossRefPubMed
25. 25.↵
    1. Lee SJ,
    2. Seo HJ,
    3. Cheon GJ, et al

    . Usefulness of integrated PET/MRI in head and neck cancer: a preliminary study. Nucl Med Mol Imaging 2014;48:98–105 doi:10.1007/s13139-013-0252-2 pmid:24900149

    CrossRefPubMed
26. 26.↵
    1. Platzek I,
    2. Beuthien-Baumann B,
    3. Schneider M, et al

    . PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging 2013;40:6–11 doi:10.1007/s00259-012-2248-z pmid:23053322

    CrossRefPubMed
27. 27.↵
    1. Grueneisen J,
    2. Sawicki LM,
    3. Schaarschmidt BM, et al

    . Evaluation of a fast protocol for staging lymphoma patients with integrated PET/MRI. PLoS One 2016;11:e0157880 doi:10.1371/journal.pone.0157880 pmid:27327617

    CrossRefPubMed
28. 28.↵
    1. Todd DJ,
    2. Kay J

    . Gadolinium-induced fibrosis. Annu Rev Med 2016;67:273–91 doi:10.1146/annurev-med-063014-124936 pmid:26768242

    CrossRefPubMed
29. 29.↵
    1. Queiroz MA,
    2. Hüllner M,
    3. Kuhn F, et al

    . Use of diffusion-weighted imaging (DWI) in PET/MRI for head and neck cancer evaluation. Eur J Nucl Med Mol Imaging 2014;41:2212–21 doi:10.1007/s00259-014-2867-7 pmid:25091219

    CrossRefPubMed
30. 30.↵
    1. Perkins NJ,
    2. Schisterman EF

    . The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670–75 doi:10.1093/aje/kwj063 pmid:16410346

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Fruehwald-Pallamar J,
    2. Czerny C,
    3. Mayerhoefer ME, et al

    . Functional imaging in head and neck squamous cell carcinoma: correlation of PET/CT and diffusion-weighted imaging at 3 Tesla. Eur J Nucl Med Mol Imaging 2011;38:1009–19 doi:10.1007/s00259-010-1718-4 pmid:21465255

    CrossRefPubMed
32. 32.↵
    1. Barakos JA,
    2. Dillon WP,
    3. Chew WM

    . Orbit, skull base, and pharynx: contrast-enhanced fat suppression MR imaging. Radiology 1991;179:191–98 doi:10.1148/radiology.179.1.2006277 pmid:2006277

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Tokuda O,
    2. Harada Y,
    3. Matsunaga N

    . MRI of soft-tissue tumors: fast STIR sequence as substitute for T1-weighted fat-suppressed contrast-enhanced spin-echo sequence. Am J Roentgenol 2009;193:1607–14 doi:10.2214/AJR.09.2675 pmid:19933655

    CrossRefPubMed
34. 34.↵
    1. Folkman J

    . Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757–63 doi:10.1056/NEJM199512283332608 pmid:7491141

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Mérida I,
    2. Avila-Flores A

    . Tumor metabolism: new opportunities for cancer therapy. Clin Transl Oncol 2006;8:711–16 doi:10.1007/s12094-006-0117-6 pmid:17074669

    CrossRefPubMed
36. 36.↵
    1. Amit M,
    2. Binenbaum Y,
    3. Trejo-Leider L, et al

    . International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head Neck 2015;37:1038–45 doi:10.1002/hed.23710 pmid:24710845

    CrossRefPubMed
37. 37.↵
    1. Yousem DM,
    2. Gad K,
    3. Tufano RP

    . Resectability issues with head and neck cancer. AJNR Am J Neuroradiol 2006;27:2024–36 pmid:17110661

    Abstract/FREE Full Text
38. 38.↵
    1. van den Brekel MW,
    2. Runne RW,
    3. Smeele LE, et al

    . Assessment of tumour invasion into the mandible: the value of different imaging techniques. Eur Radiol 1998;8:1552–57 doi:10.1007/s003300050585 pmid:9866760

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Samarin A,
    2. Hüllner M,
    3. Queiroz MA, et al

    . 18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT. Nucl Med Commun 2015;36:1165–73 doi:10.1097/MNM.0000000000000387 pmid:26397999

    CrossRefPubMed
40. 40.↵
    1. Schroeder U,
    2. Dietlein M,
    3. Wittekindt C, et al

    . Is there a need for positron emission tomography imaging to stage the N0 neck in T1-T2 squamous cell carcinoma of the oral cavity or oropharynx? Ann Otol Rhinol Laryngol 2008;117:854–63 doi:10.1177/000348940811701111 pmid:19102133

    CrossRefPubMed